Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis

被引：1
|
作者：
Wendling, Daniel [1 ]
Goupille, Philippe [2 ]
机构：
[1] Univ Franche Comte, CHRU Besancon, Serv Rhumatol, EA 4266, Besancon, France
[2] Univ Tours, CHRU Tours, Serv Rhumatol, EA 7501,GICC, Tours, France
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 12期
关键词：
ankylosing spondylitis; anti-IL-17; anti-TNF; axial spondyloarthritis; disease activity; treatment; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0094
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：857 / 860
页数：4
相关论文
共 50 条
  • [41] Moderne AntirheumatikaModern disease-modifying antirheumatic drugs
    U. Müller-Ladner
    K. Richter
    I.H. Tarner
    Der Internist, 2015, 56 : 307 - 314
  • [42] THE RELATIVE TOXICITY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    FRIES, JF
    WILLIAMS, CA
    RAMEY, D
    BLOCH, DA
    ARTHRITIS AND RHEUMATISM, 1993, 36 (03): : 297 - 306
  • [43] RATIONAL USE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    FURST, DE
    DRUGS, 1990, 39 (01) : 19 - 37
  • [44] BONE STATUS OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Miladi, S.
    Ben Ayed, H.
    Makhlouf, Y.
    Boussaa, H.
    Ouenniche, K.
    Souabni, L.
    Kassab, S.
    Chekili, S.
    Ben Abdelghani, K.
    Fazaa, A.
    Laatar, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S447 - S447
  • [45] Predictors of effectiveness of biologic disease-modifying antirheumatic drugs (bDMARD) in the treatment of psoriatic arthritis
    Brandao, Natalia Dias
    Morgado, Marina
    Oliveira, Gerusa A.
    Acurcio, Francisco de Assis
    Guerra Junior, Augusto Afonso
    Alvares-Teodoro, Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 170 - 171
  • [46] Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities
    Peterman, Nicholas J.
    Vashi, Aksal
    Govan, Devan
    Bhatia, Amrit
    Vashi, Tejal
    Kaptur, Brad
    Yeo, Eunhae G.
    Gizinski, Alison
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [47] Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs
    Taroumian, Sara
    Knowles, Susan L.
    Lisse, Jeffrey R.
    Yanes, James
    Ampel, Neil M.
    Vaz, Austin
    Galgiani, John N.
    Hoover, Susan E.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (12) : 1903 - 1909
  • [48] An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
    Knowles, Susan
    Sudano, Dominick
    Taroumian, Sara
    Ampel, Neil M.
    Galgiani, John
    Lisse, Jeffrey R.
    Hoover, Susan E.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S919 - S919
  • [49] Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    DeWitt, Esi Morgan
    Li, Yanhong
    Curtis, Jeffrey R.
    Glick, Henry A.
    Greenberg, Jeffrey D.
    Anstrom, Kevin J.
    Kremer, Joel M.
    Reed, George
    Schulman, Kevin A.
    Reed, Shelby D.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (02) : 127 - 136
  • [50] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS - STRATEGIES FOR SCREENING
    BOWEN, JG
    CROSSLEY, MJ
    HUNNEYBALL, IM
    PHARMACOLOGY & THERAPEUTICS, 1992, 56 (03) : 287 - 306
12345